Israel: A question that pops up in our minds when we hear the word ‘CANCER’ is “why haven’t we cured cancer yet?”
With Billions and billions of money raised, invested and spent on cancer research over the past decades so far has not yielded any progress in wiping out the disease from the face of the earth, Forbes reports.
So what exactly is cancer? It is a deadly evolving disease where the cancerous cells undergo a myriad of molecular and cellular changes in the host’s body which changes the shape of these cancerous cells and how they behave making it nearly impossible to kill as they become more resilient, aggressive and deadly in the body.
However as research has progressed over the past few decades, a small team of Israeli scientist have come forward posing a challenge against the deadly disease to find the complete cure within a year.
Yes, it doesn’t seem possible but according to these scientists, this could be made possible.
“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd (AEBi) ,The Jerusalem Post published.
The team of scientist have also claimed to make the first-ever cure for the deadly disease as a cheap, effective with no or minimal side-effects.
The company ‘AEBi’ was founded in the year 2000 in the ITEK incubator in the Kiryat Weizmann Science Park in Ness Ziona, Israel and is situated at the north of the Weizmann Institute of Science in Rehovot, Israel.
The company is a development-stage biopharmaceutical company which engages in the discovery and development of therapeutic peptides.
It is also the one to develop the ‘SoAP platform’, a combinatorial biology screening platform technology, which provides functional leads—agonist, antagonist, inhibitor, etc.—to very difficult targets.
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor claimed.
“Our solution will be both generic and personal,” he added.
The drug called as ‘MuTaTo’ (multi-target toxin) currently in development by AEBi under the leadership of CEO Dr. Ilan is essentially “on the scale of a cancer antibiotic–a disruptive technology of the highest order,” which shall be the potential game changer against the world’s deadliest disease ‘Cancer’.
The research team says the anti-cancer drug is based on AEBi’s SoAP technology and is being developed by using a combination of cancer-targeting peptides and a toxin that will specifically kill cancer cells.
With this technology, “scientists introduce DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. The protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.”